Graduated with a Ph.D. in Oncologic Pathology from Fudan University Shanghai Cancer Center in 2015. From 2016 to 2018, completed postdoctoral training in the Department of Pathology at Memorial Sloan Kettering Cancer Center (MSKCC) in the United States (mentor: Professor Marc Ladanyi), conducting research on the clinical application of tumor NGS testing technologies and validation of novel therapeutic targets for sarcoma. After returning to China, served as the head of the liver pathology platform, primarily diagnosing liver tumors and liver transplantation pathology; led the establishment of a tumor NGS clinical laboratory, integrating multiple platforms including PCR, NGS, FISH, and conventional pathology to meet clinical testing demands both within and outside the institution based on tissue biopsy and liquid biopsy samples. Focused on clinical and basic translational research in the molecular pathology of hepatoblastoma, lymphoma, and sarcoma, and has undertaken multiple research projects including NSFC General Program, Shanghai Science and Technology Commission Key Clinical Research Project, and Basic Free Exploration Program. Selected for talent programs including Shanghai Pudong Mingzhu Leading Talent and Shanghai Jiao Tong University School of Medicine "Double Hundred" Research Physician. Findings have been published as first or corresponding author in multiple journals including Clin Cancer Res (2 papers), Leukemia, and J Pathol, and has been invited multiple times to participate in international top academic conferences such as AMP and USCAP for academic exchange.